Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2026, Vol. 31 ›› Issue (10): 1342-1352.doi: 10.12092/j.issn.1009-2501.2026.10.005
Lin CAI1,2,5(
), Anqi WANG3, Shuojiao LI4, Peng RAO2, Yue TANG2, Wenxian YU2, Haiyun ZHOU1,5, Guoping SUN3, Jiatao LIU1,2,5,*(
)
Received:2025-10-18
Revised:2026-05-29
Online:2026-10-26
Published:2026-11-11
Contact:
Jiatao LIU
E-mail:cailin727@163.com;liujiatao@ahmu.edu.cn
CLC Number:
Lin CAI, Anqi WANG, Shuojiao LI, Peng RAO, Yue TANG, Wenxian YU, Haiyun ZHOU, Guoping SUN, Jiatao LIU. Endoplasmic reticulum stress regulates ferroptosis in hepatocellular carcinoma via TRIB3: evidence from an integrated multi-omics analysis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(10): 1342-1352.
| Name | Sequence(5' to 3') | |
| si-TRIB3-1 | Sense | GGUUGGAGUUGGAUGACAA |
| Antisense | UUGUCAUCCAACUCCAACC | |
| si-TRIB3-2 | Sense | GGGAGACAGAGAAGUGGUU |
| Antisense | AACCACUUCUCUGUCUCCC | |
| si-TRIB3-3 | Sense | GGAAGAAGCGGUUGGAGUU |
| Antisense | AACUCCAACCGCUUCUUCC | |
| TRIB3 | Forward | GGTTCCCTGTCCAGGAAGAA |
| Reverse | CCACTTCGAGCTCGTTTCTG | |
| GAPDH | Forward | GGAGCGAGATCCCTCCAAAAT |
| Reverse | GGCTGTTGTCATACTTCTCATGG | |
| GPX4 | Forward | GAGGCAAGACCGAAGTAAACTAC |
| Reverse | CCGAACTGGTTACACGGGAA | |
| SLC7A11 | Forward | TCTCCAAAGGAGGTTACCTGC |
| Reverse | AGACTCCCCTCAGTAAAGTGAC | |
| TFR1 | Forward | GGCTACTTGGGCTATTGTAAAGG |
| Reverse | CAGTTTCTCCGACAACTTTCTCT | |
| PRDX3 | Forward | ACAGCCGTTGTCAATGGAGAG |
| Reverse | ACGTCGTGAAATTCGTTAGCTT | |
Table 1 Sequence used in the manuscript
| Name | Sequence(5' to 3') | |
| si-TRIB3-1 | Sense | GGUUGGAGUUGGAUGACAA |
| Antisense | UUGUCAUCCAACUCCAACC | |
| si-TRIB3-2 | Sense | GGGAGACAGAGAAGUGGUU |
| Antisense | AACCACUUCUCUGUCUCCC | |
| si-TRIB3-3 | Sense | GGAAGAAGCGGUUGGAGUU |
| Antisense | AACUCCAACCGCUUCUUCC | |
| TRIB3 | Forward | GGTTCCCTGTCCAGGAAGAA |
| Reverse | CCACTTCGAGCTCGTTTCTG | |
| GAPDH | Forward | GGAGCGAGATCCCTCCAAAAT |
| Reverse | GGCTGTTGTCATACTTCTCATGG | |
| GPX4 | Forward | GAGGCAAGACCGAAGTAAACTAC |
| Reverse | CCGAACTGGTTACACGGGAA | |
| SLC7A11 | Forward | TCTCCAAAGGAGGTTACCTGC |
| Reverse | AGACTCCCCTCAGTAAAGTGAC | |
| TFR1 | Forward | GGCTACTTGGGCTATTGTAAAGG |
| Reverse | CAGTTTCTCCGACAACTTTCTCT | |
| PRDX3 | Forward | ACAGCCGTTGTCAATGGAGAG |
| Reverse | ACGTCGTGAAATTCGTTAGCTT | |
Fig.1 Identification of differentially expressed ferroptosis-related genes (DFRGs) A: venn diagram of GEO2R result and FRGs; B: volcano plot of differential genes between control and ER stress groups; C: heatmap of the 57 differentially expressed DFRGs.
Fig.2 GO and KEGG enrichment analyses of differentially expressed DFRGs KEGG pathway analysis of the 57 DFRGs: bubble chart (A) and circular network plot (B). GO enrichment analysis of the 57 DFRGs: bubble plot (C) and chord diagram (D).
Fig.3 Construction of protein–protein interaction (PPI) network and identification of key hub genes A: the PPI network maps about 57 differentially expressed DFRGs; B: string analysis network diagram of top15 DFRGs obtained by combining CytoHubba and MCODE algorithms.
Fig.4 Expression and correlation of differentially expressed DFRGs with liver diseases A: the expression of differentially expressed DFRGs in GSE208391 data; B: heatmap of correlation of 15 differentially expressed DFRGs; C: the correlations between DFRGs and liver diseases in comparative toxicomics database. *P<0.05, **P<0.01, ***P<0.001.
Fig.5 The role of core-DFRGs in the diagnosis and prognosis of HCC patients A: the expression levels of the 15 differentially expressed DFRGs in HCC patients according to TCGA data; B: ROC curves of candidate core-DFRGs in diagnosing HCC; C: Kaplan-Meier estimated survival curves of the core-DFRGs were constructed using TCGA clinical data. **P<0.01, ***P<0.001.
Fig.6 Over-expression of TRIB3 is associated with macrophage infiltration and poor overall survival in HCC patients A: representative images of the expression pattern of CD68 and GRP78 protein in HCC tissues and paired liver tissues (scale bar=100 μm); B: Spearman correlation analysis of TRIB3 and two ER stress markers (ATF4 and DDIT3) according to TCGA database; C: the expression levels of CD68+ cells in TRIB3low and TRIB3high HCC tissues; D: Log-rank test evaluated overall survival according to TRIB3 expression in 37 cases of HCC patients. ***P<0.001.
| Druggable gene category | Matching gene count | Matching gene (s) | Non-matching gene (s) |
| Transporter | 4 | SLC1A4, ATF4, HSPA5, SLC7A11 | DDIT3, ASNS, TRIB3 |
| Cell surface | 3 | SLC1A4, HSPA5, SLC7A11 | ATF4, DDIT3, ASNS, TRIB3 |
| Druggable genome | 3 | HSPA5, SLC7A11, TRIB3 | SLC1A4, ATF4, DDIT3, ASNS |
| Transcription factor | 3 | ATF4, DDIT3, TRIB3 | SLC1A4, HSPA5, SLC7A11, ASNS |
| Clinically actionable | 2 | DDIT3, ASNS | SLC1A4, ATF4, HSPA5, SLC7A11, TRIB3 |
| Enzyme | 2 | HSPA5, ASNS | SLC1A4, ATF4, DDIT3, SLC7A11, TRIB3 |
| Drug resistance | 1 | ASNS | SLC1A4, ATF4, DDIT3, HSPA5, SLC7A11, TRIB3 |
| Kinase | 1 | TRIB3 | SLC1A4, ATF4, DDIT3, HSPA5, SLC7A11, ASNS |
| Protease inhibitor | 1 | HSPA5 | SLC1A4, ATF4, DDIT3, SLC7A11, ASNS, TRIB3 |
| Serine-threonine kinase | 1 | TRIB3 | SLC1A4, ATF4, DDIT3, HSPA5, SLC7A11, ASNS |
| transcription factor binding | 1 | DDIT3 | SLC1A4, ATF4, HSPA5, SLC7A11, ASNS, TRIB3 |
| transcription factor complex | 1 | DDIT3 | SLC1A4, ATF4, HSPA5, SLC7A11, ASNS, TRIB3 |
Table 2 Druggable categories for the 8 core-DFRGs (Top 10)
| Druggable gene category | Matching gene count | Matching gene (s) | Non-matching gene (s) |
| Transporter | 4 | SLC1A4, ATF4, HSPA5, SLC7A11 | DDIT3, ASNS, TRIB3 |
| Cell surface | 3 | SLC1A4, HSPA5, SLC7A11 | ATF4, DDIT3, ASNS, TRIB3 |
| Druggable genome | 3 | HSPA5, SLC7A11, TRIB3 | SLC1A4, ATF4, DDIT3, ASNS |
| Transcription factor | 3 | ATF4, DDIT3, TRIB3 | SLC1A4, HSPA5, SLC7A11, ASNS |
| Clinically actionable | 2 | DDIT3, ASNS | SLC1A4, ATF4, HSPA5, SLC7A11, TRIB3 |
| Enzyme | 2 | HSPA5, ASNS | SLC1A4, ATF4, DDIT3, SLC7A11, TRIB3 |
| Drug resistance | 1 | ASNS | SLC1A4, ATF4, DDIT3, HSPA5, SLC7A11, TRIB3 |
| Kinase | 1 | TRIB3 | SLC1A4, ATF4, DDIT3, HSPA5, SLC7A11, ASNS |
| Protease inhibitor | 1 | HSPA5 | SLC1A4, ATF4, DDIT3, SLC7A11, ASNS, TRIB3 |
| Serine-threonine kinase | 1 | TRIB3 | SLC1A4, ATF4, DDIT3, HSPA5, SLC7A11, ASNS |
| transcription factor binding | 1 | DDIT3 | SLC1A4, ATF4, HSPA5, SLC7A11, ASNS, TRIB3 |
| transcription factor complex | 1 | DDIT3 | SLC1A4, ATF4, HSPA5, SLC7A11, ASNS, TRIB3 |
Fig.7 ER stress inhibits ferroptosis via up-regulating TRIB3 in HCC A: qPCR analyses the mRNA levels of GRP78 and TRIB3 in HepG2 cells treated by a series of tunicamycin (TM); B: western blot analyses of ferroptosis-related proteins after co-incubated with TM for 24 hours; C: representative images of TRIB3 protein in HCC tissues and paired liver tissues (Scale bar=200 μm for the upper panel; Scale bar=50 μm for the lower panel); D: heatmap of the correlation of the 7 ER stress marker genes; E: qPCR detected the mRNA levels of TRIB3 after transfection HepG2 cells with specific TRIB3 siRNA. Western blot and qPCR analyses of ferroptosis-related proteins (F) and mRNA (G) levels after knockdown of TRIB3 (n=3). *P<0.05, **P<0.01, ***P<0.001.
| 1 | Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71 (3): 209- 249. |
| 2 |
Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040[J]. J Hepatol, 2022, 77 (6): 1598- 1606.
doi: 10.1016/j.jhep.2022.08.021 |
| 3 |
Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma[J]. Gastroenterology, 2019, 156 (2): 477- 491.
doi: 10.1053/j.gastro.2018.08.065 |
| 4 |
Akman M, Belisario DC, Salaroglio IC, et al. Hypoxia, endoplasmic reticulum stress and chemoresistance: dangerous liaisons[J]. J Exp Clin Cancer Res, 2021, 40 (1): 28.
doi: 10.1186/s13046-020-01824-3 |
| 5 |
Fan LL, Sun GP, Ma T, et al. Melatonin reverses tunicamycin-induced endoplasmic reticulum stress in human hepatocellular carcinoma cells and improves cytotoxic response to doxorubicin by increasing CHOP and decreasing survivin[J]. J Pineal Res, 2013, 55 (2): 184- 194.
doi: 10.1111/jpi.12061 |
| 6 |
Liu JT, Fan LL, Yu HQ, et al. Endoplasmic reticulum stress causes liver cancer cells to release exosomal miR-23a-3p and up-regulate programmed death ligand 1 expression in macrophages[J]. Hepatology, 2019, 70 (1): 241- 258.
doi: 10.1002/hep.30607 |
| 7 |
Bu LJ, Yu HQ, Fan LL, et al. Melatonin, a novel selective ATF-6 inhibitor, induces human hepatoma cell apoptosis through COX-2 downregulation[J]. World J Gastroenterol, 2017, 23 (6): 986- 998.
doi: 10.3748/wjg.v23.i6.986 |
| 8 |
张亮, 廖勇群, 夏秦川, 等. 铁死亡调控信号通路以及在相关疾病中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27 (2): 227- 234.
doi: 10.12092/j.issn.1009-2501.2022.02.015 |
| 9 |
Banerjee S, Zhang W. Endoplasmic reticulum: target for next-generation cancer therapy[J]. Chembiochem, 2018, 19 (22): 2341- 2343.
doi: 10.1002/cbic.201800461 |
| 10 |
Zhou B, Lu DH, Wang AQ, et al. Endoplasmic reticulum stress promotes sorafenib resistance via miR-188-5p/hnRNPA2B1-mediated upregulation of PKM2 in hepatocellular carcinoma[J]. Mol Ther Nucleic Acids, 2021, 26, 1051- 1065.
doi: 10.1016/j.omtn.2021.09.014 |
| 11 |
丁明霞, 罗亚文, 何毅怀. 脂质过氧化介导肝损伤在肝病中的作用[J]. 安徽医学, 2025, 46 (9): 1182- 1187.
doi: 10.3969/j.issn.1000-0399.2025.09.021 |
| 12 |
Chen X, Kang R, Kroemer G, et al. Broadening horizons: the role of ferroptosis in cancer[J]. Nat Rev Clin Oncol, 2021, 18 (5): 280- 296.
doi: 10.1038/s41571-020-00462-0 |
| 13 |
Elkateb AS, Nofal S, Ali SA, et al. Camptothecin sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via suppression of Nrf2[J]. Inflammation, 2023, 46 (4): 1493- 1511.
doi: 10.1007/s10753-023-01823-4 |
| 14 |
Xu T, Ding W, Ji XY, et al. Molecular mechanisms of ferroptosis and its role in cancer therapy[J]. J Cell Mol Med, 2019, 23 (8): 4900- 4912.
doi: 10.1111/jcmm.14511 |
| 15 |
Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death[J]. Cell, 2012, 149 (5): 1060- 1072.
doi: 10.1016/j.cell.2012.03.042 |
| 16 |
Hong SH, Lee DH, Lee YS, et al. Molecular crosstalk between ferroptosis and apoptosis: emerging role of ER stress-induced p53-independent PUMA expression[J]. Oncotarget, 2017, 8 (70): 115164- 115178.
doi: 10.18632/oncotarget.23046 |
| 17 |
Xu MY, Tao J, Yang YD, et al. Ferroptosis involves in intestinal epithelial cell death in ulcerative colitis[J]. Cell Death Dis, 2020, 11 (2): 86.
doi: 10.1038/s41419-020-2299-1 |
| 18 |
Jiang XL, Zhang W, Li LF, et al. Integrated transcriptomic analysis revealed hub genes and pathways involved in sorafenib resistance in hepatocellular carcinoma[J]. Pathol Oncol Res, 2021, 27, 1609985.
doi: 10.3389/pore.2021.1609985 |
| 19 |
Zhang C, Liu XY, Jin SD, et al. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance[J]. Mol Cancer, 2022, 21 (1): 47.
doi: 10.1186/s12943-022-01530-y |
| 20 | Lachaier E, Louandre C, Godin C, et al. Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors[J]. Anticancer Res, 2014, 34 (11): 6417- 6422. |
| [1] | Feng YANG, Wei SHI, Huiling WANG, Zitong ZHENG. Ginkgetin suppresses proliferation and migration of triple-negative breast cancer cells by inducing ferroptosis via the GPX4/OTUB1 axis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(7): 865-874. |
| [2] | Ziyu WU, Ting YU, Mouwei ZHENG, Tailin GUO. Metformin inhibits diabetes induced ferroptosis in renal proximal tubular epithelial cells by up-regulating Nrf2 expression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(1): 40-47. |
| [3] | JIANG Yan, SONG Cangsang, WANG Guohui, MAO Panpan, LI Xingde. The role and mechanisms of lncRNA and miRNA in metabolic reprogramming regulation in hepatocellular carcinoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(9): 1260-1271. |
| [4] | LIN Yiyan, WU Yueying, YAN Rui, WU Dong. Research progress on the mechanism of quercetin in preventing and treating acute lung injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(9): 1272-1280. |
| [5] | WANG Zhiheng1, XING Xin1, TAO Tao2, MENG lianqin1, WANG Jun1, GUO Ping1, CHAI Lin2. SCD1 inhibitor CAY-10566 sensitizes cisplatin by inducing ferroptosis in oral squamous cell carcinoma cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(8): 1009-1016. |
| [6] | ZHAO Yahong, LI Qiang . Targeting ferroptosis offers a novel therapeutic approaches in epilepsy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(6): 828-834. |
| [7] | JIN Menghan, JIANG Suwen, HU Airong, LIN Ken, FAN Ying, WANG Jialan, ZHANG Haojin. Research progress on differential improvement and mechanism of nucleoside analogues or nucleotide analogues in HBV-related hepatocellular carcinoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(6): 835-848. |
| [8] | LANG Xu, LIU Boyu. Efficacy and safety of TACE combined with lenvatinib and PD-1 inhitibors in the treatment of hepatocellular carcinoma with portal vein tumor thrombus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(5): 648-656. |
| [9] | CHEN Zhiwen, WANG Longrong, WANG Lu. Current status and progress of targeted therapy for hepatocellular carcinoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(2): 171-182. |
| [10] |
WU Yuxing, Li Yi, YUE Xiaoqing, ZHANG Chenlu, ZHANG Yanping.
Effect of Angong Niuhuang pill combined with conventional treatment on neurological function recovery in patients with phlegm-heat internal closed cerebral hemorrhage: A randomized controlled trial based on the AMPK-PGC1α-NRF2 pathway
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(10): 1391-1399.
|
| [11] | LIU Jing, LEI Guojie, CAO Jinghao, YU Lingyan, DU Jing, WANG Ying. Mechanism of doxorubicin/copper complex induced cuproptosis in hepatocellular carcinoma cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(1): 1-10. |
| [12] | LEI Guojie, YU Yanhua, LIU Yingchao, BIAN Wenxia, DU Jing, TONG Xiangmin. Mechanism of PX-12 induced apoptosis of hepatocellular carcinoma cells through oxidative stress [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(9): 961-967. |
| [13] | ZHU Rendi, QU Biao, ZHOU Renpeng, HU Wei. Caragana sinica root inhibits Erastin-induced chondrocyte ferroptosis by blocking TRPM7 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(7): 800-808. |
| [14] | LAN Xueling, HUANG Yanni, ZHU Minmin, MA Ping, DONG Min. Advances of VEGF signalling pathway in hepatocellular carcinomar invasion and metastasis and therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(6): 707-714. |
| [15] | LI Mei, LI Qiang. Recent progress of targeting Nrf2-ferroptosis to treat brain injury after ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(2): 188-197. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||